Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii : role of a novel transferrable plasmid conferring carbapenem resistance

Heba Mohammed Refat M. Selim,Fatma Alzahraa M. Gomaa,Mohammad Y. Alshahrani,Noha A. Kamel,Khaled M. Aboshanab,Khaled M. Elsayed
DOI: https://doi.org/10.1016/j.diagmicrobio.2024.116558
IF: 2.983
2024-10-14
Diagnostic Microbiology and Infectious Disease
Abstract:This study aimed to evaluate the antimicrobial susceptibility and combination of a beta-blocker, labetalol (LAB) and meropenem (MEM) on Carbapenem-resistant (CR) A. baumannii clinical isolates. A total of 43 CR- A. baumannii were isolated of which 37 (86.6%) and 28 (65%) exhibited MDR and XDR phenotypes, respectively. Colistin and doxycycline still retain their activities in 93.1% and 72.1% of the isolates, respectively. Combining MEM with LAB at 0.25 mg /mL, decreased MIC values in 91.4% (32/35) however, at 0.5 mg /mL, it decreased MIC value and restored susceptibility to MEM in 100% and 91.4% of the tested isolates, respectively. A novel transferable plasmid pAcbGIM3 harboring aph -3', bla oxa-58, bla GIM3 and bla CTX-M3 and eight mobile genetic elements were successfully isolated from a pan-drug resistant (PDR) isolate. In conclusion, LAB-MEM is a promising combination and should be clinically examined. This is the first report of a transmissible plasmid harboring bla GIM3 gene in Egypt.
infectious diseases,microbiology
What problem does this paper attempt to address?